Dynamic changes in gene alterations during chemotherapy in metastatic castrate resistant prostate cancer

Dynamic changes in gene alterations during chemotherapy in metastatic castrate resistant prostate cancer

Abstract Docetaxel chemotherapy is a standard treatment option for metastatic castrate resistant prostate cancer (mCRPC) patients. To date, the genomic perturbations underlying the emergence of resistance in mCRPC patients during chemotherapy treatment have not been fully characterized. Previous stu...

Full description

Bibliographic Details
Main Authors: Winston Tan, Tiantian Zheng, Amy Wang, Joanna Roacho, Seng Thao, Pan Du, Shidong Jia, Jianjun Yu, Bonnie L. King, Manish Kohli
Format: Article
Language:English
Published: Nature Portfolio 2022-03-01
Series:Scientific Reports
Online Access:https://doi.org/10.1038/s41598-022-08520-6

Internet

https://doi.org/10.1038/s41598-022-08520-6

Similar Items